Silver Book reference

Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer

1 Matching Fact

Search matching Facts:
No results to display
    • Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.